To The Moon

$INCANNEX HEALTHCARE LTD(IXHL)$ IXHL is one of the clearest examples of why small-cap biotech stocks can destroy investor trust.

The biggest problem is dilution risk. In March 2026, Incannex announced a US$10 million registered direct offering priced at US$5.00 per share with accompanying warrants, and it also expanded its sales-agreement capacity by another US$50 million of common stock issuance. For existing shareholders, that creates a heavy overhang and makes it hard to feel protected.

The business is still highly speculative. In its quarterly reporting, the company said it generated no revenue for the December 2025 quarter and does not expect material revenue unless and until its drug candidates are approved. It also reported continuing operating losses.

Yes, management has talked about having roughly US$75 million in cash and no debt, and it reactivated a buyback program in late March. But for many investors, that positive message is undermined when the company can both talk about repurchasing shares and also keep open the option to issue a large amount of new stock. That mixed signal makes confidence difficult.

My view: IXHL may still appeal to high-risk biotech traders, but for ordinary investors it looks like a stock where dilution, volatility, and uncertainty can outweigh the story very quickly. I would treat it as highly speculative, not investor-friendly.